Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Announces Completion of Previously Announced Share Consolidation
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Provides Corporate Update on Upcoming Clinical Milestones
– Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently – – 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 – – Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder (“GAD”) expected
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) ( Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
– Company expects to initiate Phase 3 pivotal trial in late summer 2024 – – Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies – – Pivotal trial designs incorporate elements to address functional unblinding – – Company to
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
– Phase 3 multinational study of CYB003 expected to begin in late summer 2024 – – 30 clinical sites selected across the United States and Europe for Phase 3 CYB003 study – – 12-month efficacy results from Phase 2 study of CYB003 in MDD expected Q4 2024 – – Additional United States patent granted
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
– Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) – – Clinical site selection complete for Phase 3 multinational
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to